NCT03136185View on ClinicalTrials.gov

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 18, 2017

Primary Completion Date

March 8, 2022

Study Completion Date

March 8, 2022

Conditions
MyelofibrosisPost-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)Primary Myelofibrosis (PMF)
Interventions
DRUG

Bomedemstat

Oral (capsule) administration according to dose allocation.

Trial Locations (5)

45147

Universitatsklinikum Essen, Essen

48105

University of Michigan, Ann Arbor

Unknown

Royal Adelaide Hospital, Adelaide

Azienda Ospedaliero Universitaria Careggi, Florence

Guy's and St Thomas' Hospitals, London

All Listed Sponsors
lead

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

INDUSTRY

NCT03136185 - Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) | Biotech Hunter | Biotech Hunter